Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

Université de Montréal

$27,000.00

Multi-dimensional prioritization of prostate cancer drivers and mechanisms of treatment resistance

EF 2025-26

Résumé
Prostate cancer is the most common cancer in Canadian men and remains a major cause of cancer-related death. Early on, tumor growth relies on male hormones called androgens, and standard treatments reduce these hormones or block their effects, often leading to remission. The challenge is that many tumors eventually adapt: they continue to grow despite therapy and progress to a more aggressive, treatment-resistant form known as castration-resistant prostate cancer. At this stage, tumor cells reprogram their identity, shifting away from their original hormone-dependent state and becoming far more difficult to treat. This project aims to uncover the genetic and molecular changes that allow prostate cancer cells to withstand therapy and alter their identity. Using a CRISPR activation system, we will systematically “turn on” thousands of human genes to identify those that drive growth, promote therapeutic resistance, or restore hormone sensitivity. We will begin with large-scale screens across multiple prostate cancer cell lines to pinpoint genes regulating growth and cell identity. We will then examine how cancer cells develop resistance to drugs that target androgen signaling and the PRC2-EZH2 pathway, a major epigenetic regulator and promising therapeutic target in aggressive, hormone-independent prostate cancer. By integrating these findings, we aim to uncover genes and pathways that enable identity reprogramming and therapy tolerance. The outputs will yield prioritized candidate targets and testable mechanisms that can be advanced into preclinical studies to guide the development of improved treatment strategies.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
573235
Name
Carter Sean
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Multi-dimensional prioritization of prostate cancer drivers and mechanisms of treatment resistance
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cancer; Cell Identity Modulation; Crsipr; Functional Genomics; Gene Activation; Gene Regulatory Networks; High-Throughput Screening; Prostate; Therapeutic Resistance; Tumor Plasticity
Abstract
Prostate cancer is the most common cancer in Canadian men and remains a major cause of cancer-related death. Early on, tumor growth relies on male hormones called androgens, and standard treatments reduce these hormones or block their effects, often leading to remission. The challenge is that many tumors eventually adapt: they continue to grow despite therapy and progress to a more aggressive, treatment-resistant form known as castration-resistant prostate cancer. At this stage, tumor cells reprogram their identity, shifting away from their original hormone-dependent state and becoming far more difficult to treat. This project aims to uncover the genetic and molecular changes that allow prostate cancer cells to withstand therapy and alter their identity. Using a CRISPR activation system, we will systematically “turn on” thousands of human genes to identify those that drive growth, promote therapeutic resistance, or restore hormone sensitivity. We will begin with large-scale screens across multiple prostate cancer cell lines to pinpoint genes regulating growth and cell identity. We will then examine how cancer cells develop resistance to drugs that target androgen signaling and the PRC2-EZH2 pathway, a major epigenetic regulator and promising therapeutic target in aggressive, hormone-independent prostate cancer. By integrating these findings, we aim to uncover genes and pathways that enable identity reprogramming and therapy tolerance. The outputs will yield prioritized candidate targets and testable mechanisms that can be advanced into preclinical studies to guide the development of improved treatment strategies.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Carter, Sean
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~